London is set to become a proving ground for AI–driven medical technologies following the launch of a new regulatory sandbox designed to help innovations move more rapidly and safely into real-world NHS use.
Announced this week, the initiative is being led by the Medicines and Healthcare products Regulatory Agency (MHRA) in partnership with NHS England and London’s Health Innovation Networks (HINs). The sandbox will provide a controlled testing environment in which selected companies can deploy AI-enabled medical devices alongside clinicians across London, while working closely with regulators to generate robust real-world evidence.
The program sits at the heart of a newly unveiled London Life Sciences Strategy, which aims to make the capital the most attractive global city for life sciences innovation — while ensuring that innovation translates into better, fairer healthcare outcomes for patients.
Despite London’s strengths — including nearly 10 million patients, three of the world’s top 15 research universities, and more than 2,700 life sciences companies — promising health technologies have historically struggled to progress beyond small, localized pilots. Fragmented procurement, duplicated evaluations, and uncertainty around regulation have often slowed adoption at scale.
“What has been missing is the coordination to bring all of this together,” Chris Streather, London’s Medical Director, said in the press release. “For the first time, we have a coherent, system-wide plan to move innovations from promising pilots to widespread adoption — and to make sure the benefits reach every Londoner, not just those in the most advantaged communities.”
A controlled environment for AI innovation
The MHRA regulatory sandbox will initially focus on AI-driven devices and diagnostics, building on the agency’s existing AI Airlock program and drawing on lessons from other government initiatives such as the Financial Conduct Authority’s regulatory sandbox.
Up to 10 AI medical device manufacturers will be selected for the first phase, working with NHS providers across London to deploy technologies in live clinical settings under MHRA oversight. By enabling outcomes-based deployment, the sandbox aims to generate high-quality evidence on safety and effectiveness while offering innovators a clearer, more predictable route to adoption.
“This initiative demonstrates that regulation can be an enabler for innovation, not a barrier,” Lawrence Tallon, Chief Executive of the MHRA, said in the press release. “We need to work faster to keep pace with developments in AI to ensure that patients can safely benefit from cutting-edge technologies as they become available.”
The sandbox also responds to mounting pressures on the NHS. Adverse drug reactions alone send around 250,000 people to hospital each year, at a cost of more than £2 billion (USD $2.7 billion) annually. Meanwhile, around 90 percent of drugs fail during development, often because early testing methods struggle to predict real-world safety risks. Regulators hope that AI tools tested through the sandbox could improve safety assessments, identify side effects earlier, and reduce costly late-stage failures.
Data, funding, and procurement reform
The regulatory sandbox is one of six London-wide programs outlined in the Life Sciences Strategy, which together aim to turn the capital into a coordinated Health Innovation Zone.
Other initiatives include new London Health Innovation Funds to improve access to non-dilutive funding and coordinate up to £900 million (USD $1.2 billion) in NHS working capital for transformation projects. Reforms to procurement and contracting are also planned, enabling pan-London purchasing of innovative solutions and longer-term strategic partnerships with suppliers.
To reduce duplication in decision-making, London will introduce “Innovator Passports” through a central digital platform known as MedTech Compass. These passports will allow companies to submit a single, standardized evidence file — covering regulatory status, quality systems, data protection, cybersecurity, and clinical evidence — that can be reviewed by multiple NHS buyers.
The strategy also expands safe access to London’s vast health data assets. Through OneLondon, approved researchers and innovators will be able to use de-identified data from nine million Londoners, spanning primary care, hospitals, mental health, and social care, to support research into areas such as cardiovascular disease and health inequalities.
Focus on outcomes, not technology
Crucially, the strategy emphasizes that innovation is not an end in itself. Health inequalities across London have worsened since the Covid-19 pandemic, and the new programs are explicitly focused on outcomes such as earlier cancer detection, better management of long-term conditions, and narrowing gaps in care.
“Londoners deserve the best that modern medicine has to offer,” Caroline Clarke, Director of NHS London, said in the press release. “This program is about making sure the NHS in London can adopt the latest technologies quickly, safely, and in a way that genuinely improves care for patients.”
For industry, the sandbox provides a clearer and more predictable regulatory route for AI technologies designed to support drug discovery, pharmacovigilance, and clinical development. By working alongside regulators from the outset, companies can refine tools in line with regulatory expectations, potentially reducing delays later in development.
As expressions of interest open next month, the partners behind the program position London not only as a testbed for AI in healthcare delivery, but as a platform for generating the real-world evidence needed to support safer, more efficient drug discovery and development.
